Published in Drug Law Weekly, March 24th, 2009
Cytograft’s living human product, called Lifeline™ (trade-name not associated with Lifeline Cell Technology), is a promising technology that will be used as a coronary graft for coronary bypass procedures, as a peripheral graft to prevent...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.